Delta 9About Us


Company History


Delta 9, which was founded by the father and son team of Bill and John Arbuthnot in 2012, obtained a production license under the Marihuana for Medical Purposes Regulations in December 2013, followed by a license to distribute medical cannabis in March 2014, becoming the 4th Licensed Producer of medical cannabis in Canada.

Since that time, Delta 9 has established itself in its 80,000 square foot production facility in East Winnipeg and grown from 2 employees to approximately 30 full-time employees and 20 part-time employees. Delta 9 is focused on growing small batch, hand trimmed, high quality medical cannabis strains in proprietary Grow Pod systems, using our standardized hydroponic growing methodologies. Delta 9 currently has a growing rotation of approximately 20 different genetic strains of cannabis that are available to our 2,000 medical patients across Canada.

In May 2017, Delta 9 began working towards becoming a publicly traded company entering into an amalgamation agreement with SVT Capital Corp. On November 1st, 2017, Delta 9 Cannabis Inc. (formerly SVT Capital Corp.) (the “Company“) announced that it had completed its intended reverse takeover transaction (the “Transaction”), pursuant to which the Company has acquired all of the issued and outstanding shares of Delta 9 Bio-Tech Inc. (“Delta 9”) by way of a three-cornered amalgamation among the Company, Delta 9 and 10240907 Canada Corp. (“Newco”). The Company then began trading as a Tier 2 Industrial Issuer on the TSX Venture Exchange (the “TSXV”) under the symbol “NINE” at market open on Monday, November  6, 2017.

“This represents a significant milestone for Delta 9 as we look to aggressively expand our domestic production facilities and international opportunities,” said the Company’s Chairman, President and director, Bill Arbuthnot.  “The capital raised under the Concurrent Financing will allow us to scale up our growing operations, enabling us to take advantage of the tremendous opportunities in the medical cannabis market. In doing so, we plan to become a premier choice for patients who want a consistent, high-quality, standardized product that they can rely on.”

In 2017, Delta 9 has constructed 28 of its self-designed ‘grow pods’, with the intended build out to include upwards of 600 grow pods in its current 80,000 square foot building in Winnipeg. Production capacity is expected to increase from the current 1,000 kilograms per year, to 17,000 kilograms of high grade cannabis by 2020 with the creation of 300 new jobs.

The future is green for Delta 9 Cannabis Inc.


Looking for investor information?